Human Papillomavirus (HPV) Therapeutics Market Analysis North America,Europe,Asia,Rest of World (ROW) - US,Canada,Brazil,Germany,China - Size and Forecast 2023-2027

Human Papillomavirus (HPV) Therapeutics Market Forecast 2023-2027

The human papillomavirus (HPV) therapeutics market size is estimated to grow by USD 953.3 million at a CAGR of 5.15% between 2022 and 2027. The market is driven by various factors, including the emergence of vaccines and the ongoing development of oral vaccines specifically for HPV. With a strong focus on disease progression, the market aims to combat HPV-related conditions effectively. These advancements are crucial in providing better treatment options and preventing the spread of HPV infections. As the demand for innovative therapeutics grows, the market strives to address the challenges posed by HPV-related diseases through continuous research and development efforts. This market research and growth also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, this Human Papillomavirus Therapeutics Market Analysis Report includes historic market data from 2017 to 2021.

What will be the Size of the Human Papillomavirus (HPV) Therapeutics Market During the Forecast Period?

To learn more about this Human Papillomavirus Therapeutics Market Analysis Report, Download Report Sample

The Human Papillomavirus Therapeutics Market Research Analysis Report is driven by various factors, including the prevalence of HPV infection, which is a sexually transmitted infection (STI) associated with genital warts and various diseases. The market encompasses vaccines such as quadrivalent, quadrivalent, and nonavalent vaccines, known for their efficacy and protection against HPV-related diseases. Vaccination policies and segments like polyvalent and bivalent play a crucial role in combating diseases like anal cancer, vulvar & vaginal cancer, penile cancer, and oropharyngeal cancer. Public & private alliances are crucial for campaigns and initiatives aimed at screening and immunization programs, which are vital in reducing the burden of cervical cancer. However, the supply shortage and stringent regulation poses a challenge, even as innovative vaccines and government funding support initiatives for early screening and diagnosis of HPV infections.

Human Papillomavirus Therapeutics Market Dynamics and Customer Landscape

The Human Papillomavirus Therapeutics Market Forecast Report is witnessing a surge in demand due to the increasing prevalence of HPV infection, a common sexually transmitted infection (STI) linked to genital warts and various diseases. The market offers quadruvalent, quadrivalent, and nonavalent vaccines, ensuring efficacy and protection against HPV-related conditions. Vaccination policies focus on both the polyvalent and bivalent segments, targeting anal, vulvar, vaginal, penile, and oropharyngeal cancers. Public-private alliances drive campaigns and initiatives for screening and immunization programs, aiming to reduce the burden of cervical cancer. However, supply shortages of HPV tests hinder early diagnosis and treatment, prompting the need for innovative vaccines and government funding in immunization programs. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, Human Papillomavirus Therapeutics Market Trends, and challenges. A holistic Human Papillomavirus Therapeutics Market Size Analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Human Papillomavirus Therapeutics Market Driver

The advent of vaccines is notably driving the market growth. According to the CDC, approximately one-fourth of the population in the US has HPV, and it is the most common sexually transmitted infection. Vaccines have strong efficacy in the prevention of various disease-causing viruses. They are highly effective in the prevention of various indications. 

There are three approved vaccines for HPV, namely GARDASIL, GARDASIL 9, and CERVARIX, all of which are approved to prevent and treat HPV type 16 and type 18. Vendors are researching vaccines for the prevention and treatment of HPV. For instance, MedImmune, a subsidiary of AstraZeneca, is conducting research on the development of MEDI0457, a vaccine that is being studied to prevent cervical cancer and head and neck cancer caused by HPV type 16 and type 18. Hence, the increasing research and advances in vaccines are expected to drive the growth of the global Human Papillomavirus Therapeutics Market Size during the forecast period.

Significant Human Papillomavirus Therapeutics Market Trends

The R&D of new drugs for Orthostatic Hypotension (OH) treatment is a key trend influencing the market growth. OH refers to an abnormal drop in blood pressure and is linked to a high risk of fatalities, syncope, falls, and cognitive decline. Certain cardiovascular and psychotropic drugs lead to drug-related OH. Other risk factors include comorbidities, advanced age, neurogenic autonomic dysfunction, and others.

Individuals with postural orthostatic tachycardia syndrome (POTS) face orthostatic hypotension. Their heart rate rises upon standing, along with symptoms such as dizziness, syncope, weakness, migraines, chronic aches and pains, gastrointestinal issues, and exhaustion. There is a high unmet need for drugs in the OH drugs market due to a lack of approval with substantial clinical efficiency and a high safety profile. Hence, the increasing focus on the R&D of novel drugs will create a positive impact on the use of HPV vaccines and the Human Papillomavirus Therapeutics Market Size.

Major Human Papillomavirus Therapeutics Market Challenges

The lack of curative therapies may impede the market growth. This is a highly prevalent virus. According to the CDC, in the US, the prevalence of this was about 25% in 2018. The approved vaccines decrease the risk of but do not completely ensure its prevention.

The global market does not have any curative methods for indications caused. Curative therapies are still in the early stages of development by various research institutions and vendors. As a result, the mortality rate due to this is increasing. Therefore, the preference for alternative treatment options such as radiation therapy and cryotherapy is increasing. 

Key Human Papillomavirus Therapeutics Market Customer Landscape

The market research report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the Human Papillomavirus Therapeutics Market Analysis Report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies and the Human Papillomavirus Therapeutics Market Size. 

Global Human Papillomavirus Therapeutics Market Customer Landscape

Who are the Major Human Papillomavirus (HPV) Therapeutics Market Companies?

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

2A Pharma ApS - The company offers L2 based HPV vaccine. It also offers vaccines and therapeutics based on the AAVLP platform.

The Human Papillomavirus Therapeutics Market Analysis Report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

• AbbVie Inc.
• Bavarian Nordic AS
• BioVaxys Technology Corp.
• F. Hoffmann La Roche Ltd.
• GlaxoSmithKline Plc
• ISA Pharmaceuticals BV
• Serum Institute of India Pvt. Ltd.
• Walvax Biotechnology Co. Ltd.
• Xiamen Innovax Biotech Co. Ltd.
• Merck and Co. Inc.
• Bausch Health Co. Inc.
• Inovio Pharmaceuticals Inc.

Qualitative and quantitative Human Papillomavirus Therapeutics Market Size Analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

Human Papillomavirus Therapeutics Market Segmentation

In the Global Human Papillomavirus Therapeutics Market, the route of administration plays a crucial role in delivering effective treatments. With a rise in prevalence, public & private alliances focus on administering HPV therapeutics efficiently. Antibodies are administered through various routes to tackle non-emergency diseases and reduce cervical cancer cases. Approval of new HPV vaccines drives industry demand, but stringent regulation ensures safety and efficacy. The end user, whether public health programs or private healthcare providers, ensures the appropriate administration of HPV therapeutics to combat the virus effectively.

By Route of Administration

The market share by the parenteral segment will be significant during the forecast period as forecasted in this Human Papillomavirus Therapeutics Market Analysis Growth Report. The market is dominated by vaccines administered through the parenteral route, such as under the skin, in a muscle, in a vein, and around the spinal cord. This route helps the vaccines in reaching the HPV-affected area without losing efficacy. 

Get a glance at the market contribution of various segments Request a PDF Sample

The parenteral segment was valued at USD 2.55 billion in 2017 and continued to grow until 2021. The increasing awareness about these and the strong efficacy of vaccines toward preventing this from progressing into cancer or other indications are expected to positively impact this segment during the forecast period. As a result, numerous people are undergoing vaccination, which is increasing the share of the segment. Therefore, the parenteral segment of the global market is expected to grow during the forecast period.

Key Regions for the Human Papillomavirus Therapeutics Market

For more insights on the market share of various regions Request PDF Sample now!

North America is estimated to account for 50% of the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional Human Papillomavirus Therapeutics Market Trends and drivers that shape the market during the forecast period.

The high sales of approved therapeutics and vaccines and the strong prevalence of various types of HPV are driving the growth of the market in North America. According to the CDC, this is the most common sexually transmitted virus in the US. They can also lead to various types of indications, such as cancer, genital warts, and multiple other infections. Therefore, there is a need to develop advanced prevention and treatment options. The pipeline in the region has multiple vaccines, which are expected to be launched during the second half of the forecast period. Advances in research on pipeline molecules are expected to contribute to the Human Papillomavirus Therapeutics Market Analysis Growth Report.

Human Papillomavirus Therapeutics Market Analyst Overview

The Global HPV (human papillomavirus) infection market is witnessing significant growth due to the rise in HPV infections, a sexually transmitted infection (STI) linked to various diseases, including vulvar & vaginal cancer, penile cancer, and oropharyngeal cancer. Vaccination policies, especially for quadruvalent, quadrivalent, and nonavalent vaccines, aim to improve efficacy and protection against HPV-related diseases. The polyvalent and bivalent segments of HPV vaccines are in high demand, leading to collaborations between public & private alliances for campaigns and initiatives. With a reduction in cervical cancer burden, there's a growing demand for HPV vaccine and early screening programs, supported by government funding and stringent regulations for approval of new HPV vaccines. The industry is focusing on developing innovative vaccines to combat the increasing prevalence of HPV infections and related diseases.

The market is witnessing increased demand due to the rise in the prevalence of diseases linked to HPV, such as cervical cancer. HPV therapeutics are divided into polyvalent segment and bivalent segment, catering to different end user needs. Antibodies developed for HPV are crucial in screening and immunization programs aimed at combating the burden of cervical cancer. However, the industry faces challenges like supply shortage and stringent regulation. The demand for HPV vaccine is growing, driven by immunization programs worldwide. Despite being non-emergency diseases, the importance of early diagnosis through HPV tests is emphasized. As governments continue to invest in the human papillomavirus infection program, the market for HPV therapeutics is expected to grow further, provided supply meets the rising industry demand.

The market is witnessing significant growth due to the rising prevalence of HPV strains, necessitating effective treatments. HPV therapeutics cater to different disease indications in both girls and boys. Vaccines like the quadrivalent and nonavalent vaccines are crucial in combating HPV-related diseases, including cervical cancer and related cancer screenings. Physicians play a pivotal role in administering these vaccines to men and women, while government entities and private organizations support human papillomavirus infection program and market expansion efforts. However, stringent regulations and the supply shortage remain a challenge. The demand for HPV vaccine is expected to increase post-pandemic, highlighting the pre-pandemic nature of HPV infections and the importance of cervical cancer screening.

Segment Overview

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in USD Million for the period 2023 to 2027, as well as historical data from 2017 to 2021 for the following segments. 

• Route of Administration Outlook 
  • Parenteral 
  • Topical 

• Indication Outlook 
  • Cervical cancer
  • Anal cancer 
  • Vulvar and vaginal cancer
  • Others 

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • ROW
    • Australia
    • Argentina
    • Rest of the world

Human Papillomavirus (HPV) Therapeutics Market Scope
Report Coverage	Details
Page number	161
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 5.15%
Market growth 2023-2027	USD 953.3 million
Market structure	Concentrated
YoY growth 2022-2023(%)	4.24
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 50%
Key countries	US, Canada, Brazil, Germany, and China
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	2A Pharma ApS, AbbVie Inc., Bavarian Nordic AS, BioVaxys Technology Corp., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, ISA Pharmaceuticals BV, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Xiamen Innovax Biotech Co. Ltd., Merck and Co. Inc., Bausch Health Co. Inc., and Inovio Pharmaceuticals Inc.
Market dynamics	Human Papillomavirus Therapeutics Market Size Analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, Human Papillomavirus Therapeutics Market Analysis Growth Report, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our Human Papillomavirus Therapeutics Market Analysis Report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
• Precise estimation of the Human Papillomavirus Therapeutics Market Size and its contribution to the parent market
• Accurate predictions about upcoming Human Papillomavirus Therapeutics Market Trends and analysis and changes in consumer behavior
• Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
• Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive Human Papillomavirus Therapeutics Market Size Analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this Human Papillomavirus Therapeutics Market Analysis Report to meet your requirements. Get in touch